WO2022181786A1 - 育毛剤 - Google Patents
育毛剤 Download PDFInfo
- Publication number
- WO2022181786A1 WO2022181786A1 PCT/JP2022/008010 JP2022008010W WO2022181786A1 WO 2022181786 A1 WO2022181786 A1 WO 2022181786A1 JP 2022008010 W JP2022008010 W JP 2022008010W WO 2022181786 A1 WO2022181786 A1 WO 2022181786A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hair
- palmitoyl dipeptide
- adenosine
- hair restorer
- growth
- Prior art date
Links
- 230000003779 hair growth Effects 0.000 title claims abstract description 28
- 210000004209 hair Anatomy 0.000 claims abstract description 98
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims abstract description 96
- 210000004919 hair shaft Anatomy 0.000 claims abstract description 52
- BVYVWYKOCOGULA-JBUMCTQMSA-N (2s,3r)-2-[[(2s)-4-amino-2-[[(2s)-2-[[(2s)-6-amino-2-(hexadecanoylamino)hexanoyl]amino]-3-methylbutanoyl]amino]butanoyl]amino]-3-hydroxybutanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O BVYVWYKOCOGULA-JBUMCTQMSA-N 0.000 claims abstract description 47
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims abstract description 47
- 229960005305 adenosine Drugs 0.000 claims abstract description 47
- 239000004480 active ingredient Substances 0.000 claims abstract description 28
- 230000012010 growth Effects 0.000 claims abstract description 18
- 210000004709 eyebrow Anatomy 0.000 claims abstract description 11
- 210000000720 eyelash Anatomy 0.000 claims abstract description 10
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 40
- QJQNWKPSKDLCOX-UHFFFAOYSA-N 3,3-diamino-2-hydroxybutanoic acid Chemical compound NC(C(C(=O)O)O)(C)N QJQNWKPSKDLCOX-UHFFFAOYSA-N 0.000 claims description 38
- 239000000203 mixture Substances 0.000 claims description 35
- 238000009472 formulation Methods 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 10
- 230000001737 promoting effect Effects 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 230000003752 improving hair Effects 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 27
- 239000003795 chemical substances by application Substances 0.000 abstract description 25
- 230000014509 gene expression Effects 0.000 abstract description 19
- 230000002500 effect on skin Effects 0.000 abstract description 16
- MSTCKFAZFCWNSK-NSVAZKTRSA-N (2s)-4-amino-2-[[(2s)-2-[[(2s)-6-amino-2-(hexadecanoylamino)hexanoyl]amino]-3-methylbutanoyl]amino]butanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCN)C(O)=O MSTCKFAZFCWNSK-NSVAZKTRSA-N 0.000 abstract description 6
- 238000002360 preparation method Methods 0.000 abstract description 6
- 108090000623 proteins and genes Proteins 0.000 abstract description 4
- 210000004761 scalp Anatomy 0.000 description 30
- 210000004027 cell Anatomy 0.000 description 21
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 18
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 18
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 10
- 230000031774 hair cycle Effects 0.000 description 10
- 239000003814 drug Substances 0.000 description 9
- 230000004570 RNA-binding Effects 0.000 description 8
- 230000006872 improvement Effects 0.000 description 8
- 239000002537 cosmetic Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000002299 complementary DNA Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 101150112014 Gapdh gene Proteins 0.000 description 4
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 229960003632 minoxidil Drugs 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- 201000004384 Alopecia Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000003656 anti-hair-loss Effects 0.000 description 3
- 238000010804 cDNA synthesis Methods 0.000 description 3
- 230000003648 hair appearance Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- SJZRECIVHVDYJC-UHFFFAOYSA-N 4-hydroxybutyric acid Chemical compound OCCCC(O)=O SJZRECIVHVDYJC-UHFFFAOYSA-N 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 208000001840 Dandruff Diseases 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 description 2
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 2
- 101000993347 Gallus gallus Ciliary neurotrophic factor Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000004909 Moisturizer Substances 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- -1 cataplasms Substances 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 229940098448 fibroblast growth factor 7 Drugs 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 210000003780 hair follicle Anatomy 0.000 description 2
- 230000003676 hair loss Effects 0.000 description 2
- 208000024963 hair loss Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000016507 interphase Effects 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 230000001333 moisturizer Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000003797 telogen phase Effects 0.000 description 2
- 210000003556 vascular endothelial cell Anatomy 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 241001340526 Chrysoclista linneella Species 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 206010068168 androgenetic alopecia Diseases 0.000 description 1
- 201000002996 androgenic alopecia Diseases 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 229920006318 anionic polymer Polymers 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000003778 catagen phase Effects 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000002734 clay mineral Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000010410 dusting Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000008266 hair spray Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000013615 primer Substances 0.000 description 1
- 239000002987 primer (paints) Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000003813 thin hair Effects 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 239000003860 topical agent Substances 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 239000004034 viscosity adjusting agent Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/606—Nucleosides; Nucleotides; Nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/591—Mixtures of compounds not provided for by any of the codes A61K2800/592 - A61K2800/596
Definitions
- the present invention relates to a hair restorer. More specifically, it relates to a hair restorer that is an external preparation containing palmitoyl dipeptide-5 diaminobutyroylhydroxythreonine, palmitoyl dipeptide-5 diaminohydroxybutyric acid, and adenosine.
- Hair growth repeats growth and shedding according to a hair cycle (hair cycle) consisting of a growth phase, a regression phase, and a resting phase.
- the symptoms of androgenetic alopecia are that the balance of the hair cycle is lost due to some cause, the period of growth period is shortened, the proportion of telogen hair is increased, and the hair becomes vellus (downy hair).
- Histologically it has been reported that the size of anagen hair follicles is smaller than that of healthy scalp, the development of dermal papilla is poor, and the capillary network surrounding hair follicles is reduced (Non-Patent Document 1).
- hair restorers that improve hair growth and hair type/hair quality.
- active ingredients that contribute to the regulation of the hair cycle, which is the life cycle of hair, have been proposed and are being marketed as hair restorers.
- vascular endothelial growth factor is a growth factor that acts specifically on vascular endothelial cells isolated from the culture medium of pituitary foliculo-stellate (stellate follicle) cells, and promotes the proliferation of vascular endothelial cells. It is known that adenosine promotes the angiogenesis process and enhances vascular permeability. It is clear that when adenosine acts on human dermal papilla cells, it promotes the expression of vascular endothelial growth factor (VEGF). In addition, it has been revealed that the expression of growth factors such as fibroblast growth factor 7 (FGF-7) is promoted (see Patent Document 1, Non-Patent Documents 2-3). .
- FGF-7 fibroblast growth factor 7
- Non-Patent Document 4 Adenosine has no reports of major side effects in human clinical trials, and the mechanism of improving thinning hair is not directly related to the regulation of sex hormones. has been proposed and put on the market (Non-Patent Document 4).
- Palmitoyldipeptide-5-diaminobutyroylhydroxythreonine and palmitoyldipeptide-5-diaminohydroxybutyric acid are known as components of cosmetic raw materials (see Patent Document 2). However, there is no report on the hair growth effect of these ingredients.
- An object of the present invention is to provide a hair restorer having an excellent hair growth effect.
- palmitoyl dipeptide-5 diaminobutyroyl hydroxythreonine and palmitoyl dipeptide-5 diaminohydroxybutyric acid and adenosine are effective ingredients for hair growth.
- the inventors have found that the activity can be exhibited, and have completed the present invention.
- a first means of the present invention for solving the above problems is a hair restorer characterized by containing palmitoyl dipeptide-5 diaminobutyroylhydroxythreonine and palmitoyl dipeptide-5 diaminohydroxybutyric acid, and adenosine as active ingredients. is an agent.
- the second means of the present invention for solving the above problems is characterized by containing palmitoyl dipeptide-5 diaminobutyroylhydroxythreonine and palmitoyl dipeptide-5 diaminohydroxybutyric acid as active ingredients, and is used in combination with adenosine. It is a hair restorer for
- the third means of the present invention for solving the above problems is characterized by containing adenosine as an active ingredient, which is used in combination with palmitoyl dipeptide-5 diaminobutyroylhydroxythreonine and palmitoyl dipeptide-5 diaminohydroxybutyric acid. It is a hair restorer for
- the fourth means of the present invention for solving the above problems is the hair restorer according to any one of the first to third means of the present invention, which is used for promoting hair shaft growth or hair growth. is.
- a fifth means of the present invention for solving the above-mentioned problems is the hair restorer according to any one of the first to fourth means of the present invention, which is used for improving hair shaft elongation speed. is.
- the sixth means of the present invention for solving the above problems is the hair restorer according to any one of the first to fourth means of the present invention, which is used for improving the maximum length of hair shafts. is.
- the seventh means of the present invention for solving the above problems is the hair restorer according to any one of the first to fourth means of the present invention, which is used for increasing the diameter of the hair shaft. be.
- the eighth means of the present invention for solving the above problems is the hair restorer according to any one of the first to fourth means of the present invention, which is used for increasing the number of hairs. .
- the ninth means of the present invention for solving the above problems is the hair restorer according to any one of the first to eighth means of the present invention, which is a solution.
- a tenth means of the present invention for solving the above problems is the hair restorer according to any one of the first to ninth means of the present invention for hair, bristles, eyebrows and/or eyelashes. is an agent.
- the eleventh means of the present invention for solving the above problems has a step of incorporating palmitoyl dipeptide-5 diaminobutyroylhydroxythreonine and palmitoyl dipeptide-5 diaminohydroxybutyric acid, and adenosine into a formulation as active ingredients.
- a method for producing a hair restorer characterized by:
- the twelfth means of the present invention for solving the above problems is characterized by comprising a step of incorporating palmitoyl dipeptide-5 diaminobutyroylhydroxythreonine and palmitoyl dipeptide-5 diaminohydroxybutyric acid into a formulation as active ingredients. , a method for producing a hair restorer for combined use with adenosine.
- the thirteenth means of the present invention for solving the above problems is palmitoyl dipeptide-5 diaminobutyroyl hydroxythreonine and palmitoyl dipeptide-5 diamino, characterized by comprising a step of incorporating adenosine as an active ingredient in a formulation.
- the fourteenth means of the present invention for solving the above problems is a hair restorer comprising a formulation containing palmitoyl dipeptide-5 diaminobutyroylhydroxythreonine and palmitoyl dipeptide-5 diaminohydroxybutyric acid and a formulation containing adenosine It is a drug kit.
- the fifteenth means of the present invention for solving the above problems is a hair restorer for combined use with adenosine, comprising a formulation containing palmitoyl dipeptide-5 diaminobutyroylhydroxythreonine and palmitoyl dipeptide-5 diaminohydroxybutyric acid. It's a kit.
- the sixteenth means of the present invention for solving the above problems is a hair restorer for combined use with palmitoyl dipeptide-5 diaminobutyroyl hydroxythreonine and palmitoyl dipeptide-5 diaminohydroxybutyric acid, which contains an adenosine-containing formulation. It's a kit.
- the seventeenth means of the present invention for solving the above problems is the administration of palmitoyl dipeptide-5 diaminobutyroylhydroxythreonine and palmitoyl dipeptide-5 diaminohydroxybutyric acid, and adenosine as active ingredients, It is a hair growth method.
- An eighteenth means of the present invention for solving the above problems is a hair restoration method comprising administering the hair restorer according to any one of the first to tenth means of the present invention to a subject. .
- Another means of the present invention for solving the above problems is a scalp care agent containing palmitoyl dipeptide-5 diaminobutyroylhydroxythreonine and palmitoyl dipeptide-5 diaminohydroxybutyric acid, and adenosine as active ingredients.
- a scalp care agent containing palmitoyl dipeptide-5 diaminobutyroylhydroxythreonine and palmitoyl dipeptide-5 diaminohydroxybutyric acid, and adenosine as active ingredients. It is a scalp symptom improvement method including administering.
- palmitoyl dipeptide-5 diaminobutyroyl hydroxythreonine palmitoyl dipeptide-5 diaminohydroxybutyric acid, and adenosine are used as active ingredients of a hair restorer, which is an external preparation, so that hair, pubic hair, eyebrows and /
- a hair restorer which is an external preparation, so that hair, pubic hair, eyebrows and /
- an excellent hair restorer and scalp care agent exhibiting the effects of promoting hair shaft growth in eyelashes, improving the speed of hair shaft elongation, improving the maximum length of the hair shaft, increasing the diameter of the hair shaft, and the scalp care effect are provided. becomes.
- Figure 1 shows a mixture of minoxidil, adenosine, palmitoyl dipeptide-5 diaminobutyroyl hydroxythreonine and palmitoyl dipeptide-5 diaminohydroxybutyrate, and palmitoyl dipeptide-5 diaminobutyroyl hydroxythreonine, palmitoyl dipeptide-5 diamino in human dermal papilla cells.
- Fig. 10 is a graph showing changes in VEGF gene expression level due to stimulation with hydroxybutyric acid and adenosine for 72 hours.
- the active ingredients of the hair restorer and scalp care agent which are external preparations according to the present invention, are palmitoyl dipeptide-5 diaminobutyroyl hydroxythreonine (Palm-Lys-Val-Dab-Thr-OH), It consists of Palmitoyl Dipeptide-5 Diaminohydroxybutyrate (Palm-Lys-Val-Dab-OH)) and adenosine.
- the concentrations of palmitoyl dipeptide-5 diaminobutyroylhydroxythreonine and palmitoyl dipeptide-5 diaminohydroxybutyric acid, which are active ingredients in the hair restorer and scalp care agent of the present invention, and adenosine are 0.001 to 20% by weight. More specifically, it is 0.005 to 10% by weight.
- the hair restorer and scalp care agent of the present invention are pharmaceuticals, quasi-drugs, cosmetics including cosmetics for hair, lashes, eyebrows and/or eyelashes, and cosmetics for the scalp, and ointments, cataplasms, liniments, lotions, and liquids for external use. , dusting agents, creams, gels, milky lotions, hair tonics, hair sprays, microneedles, etc., but not limited to these.
- the hair restorer and scalp care agent of the present invention can be produced through a step of incorporating palmitoyl dipeptide-5 diaminobutyroylhydroxythreonine, palmitoyl dipeptide-5 diaminohydroxybutyric acid, and adenosine as active ingredients.
- the hair restorer and scalp care agent for combined use with adenosine of the present invention undergoes a step of containing palmitoyl dipeptide-5 diaminobutyroylhydroxythreonine and palmitoyl dipeptide-5 diaminohydroxybutyric acid as active ingredients, , palmitoyldipeptide-5-diaminobutyroylhydroxythreonine and palmitoyldipeptide-5-diaminohydroxybutyric acid to be used in combination with a hair restorer and a scalp care agent can be produced through a step of incorporating adenosine as an active ingredient. Furthermore, in addition to the above steps, if desired, a step of adding additives for formulation may be added.
- the dosage form of these formulations is , may be the same dosage form or a combination of different dosage forms, and may be provided as a kit for providing formulations of those dosage forms.
- Components of these additives include, for example, excipients, stabilizers, flavoring agents, bases, dispersants, diluents, anionic surfactants, amphoteric surfactants, nonionic surfactants, cationic surfactants, Active agents, anionic polymers, nonionic polymers, ethylene oxide/propylene oxide block copolymers, alcohols, emulsifiers, percutaneous absorption enhancers, pH adjusters, preservatives, coloring agents, oils and fats, mineral oils, etc.
- the hair restorer and scalp care agent of the present invention may further contain known ingredients having effects such as hair growth, hair restoration, and hair nourishing.
- the dosage of the active ingredient per administration of the hair restorer and scalp care agent in the means of the present invention can be adjusted so that the effects of the hair restorer and scalp care agent of the present invention are exhibited.
- the dosage can be, for example, 0.005 to 200 mg, specifically 0.05 to 100 mg, and more specifically 0.5 to 10 mg.
- the administration frequency of the hair restorer and scalp care agent of the present invention can be once or multiple times so that the effects of the hair restorer and scalp care agent of the present invention are exhibited.
- the frequency of administration of the hair restorer and scalp care agent of the present invention can be, for example, 1 to 6 times per day. Specifically, it can be 1 to 3 times per day, more specifically 1 to 2 times per day.
- the hair restorer and scalp care agent of the present invention relate to promotion of hair shaft growth, hair growth and prevention of hair loss, preferably promotion of hair shaft growth and hair growth.
- promoting hair shaft growth means improving the hair shaft elongation speed, improving the maximum hair shaft length, and/or increasing the hair shaft diameter.
- hair growth means that hair growth has stopped at a site where hair does not grow (the hair shaft does not protrude from the epidermis) or where the number of hairs is small, or the ability to grow hair is reduced. It means to promote the growth of new hairs from the pores to increase the number of hairs, in particular, to shorten the resting phase in the hair cycle and / or to restart the stopped hair cycle. .
- having a hair shaft growth promoting effect means acting favorably on hair shaft growth promotion, and the property showing the hair shaft growth promoting effect is referred to as “hair shaft growth promoting activity”.
- has a hair growth effect means that it acts favorably on hair growth, and the property showing the hair growth effect is referred to as “hair growth promoting activity”.
- hair loss refers to a phenomenon in which hair shafts fall out of pores, and specifically refers to an increase in inhibitory cytokines that inhibit cell proliferation and cell death. Attributes that demonstrate anti-hair loss efficacy are referred to as "anti-hair loss activity.”
- anti-hair loss activity Attributes that demonstrate anti-hair loss efficacy are referred to as "anti-hair loss activity.”
- the term “has an anti-hair loss effect” means that the number of hair shafts falling out from pores is reduced through the inhibition or reduction of inhibitory cytokines and the suppression of cell death. It is a physiological phenomenon that is different from the attribute that indicates the hair effect.
- scalingp symptoms means symptoms such as dandruff, rough skin, dry scalp, erythema, itching, and pimples.
- scaling symptom improvement means suppression or improvement of dandruff, rough skin, dryness of the scalp, erythema, itching, pimples, and the like.
- the hair restorer of the present invention can be used to improve the elongation speed of hair shafts or the maximum length of hair shafts. Then, the hair shaft elongation speed can be improved, for example, by about 110% at maximum, and specifically by about 25 to 110%, compared to the hair shaft elongation speed in the standard data of the hair cycle. More specifically, it can be improved by about 33 to 110%.
- the maximum length of the hair shaft can be improved, for example, by about 49% at maximum, specifically by about 1 to 49%, compared to the maximum length of the hair shaft in the standard data of the hair cycle. More specifically, it can be improved by about 2 to 49%.
- the hair restorer of the present invention can be used to increase the diameter of hair shafts.
- the hair restorer of the present invention causes new hairs to grow from pores where hair growth has stopped (no hair shafts protrude from the epidermis) or where there are few hairs, or where hair growth ability has decreased. It can be used to promote hair growth to increase hair number, and in particular can be used to shorten the telogen phase in the hair cycle and/or to restart stopped hair cycles.
- the hair restorer and scalp care agent of the present invention can be used not only for humans but also for animals such as livestock and pets.
- an external preparation containing palmitoyl dipeptide-5 diaminobutyroylhydroxythreonine, palmitoyl dipeptide-5 diaminohydroxybutyric acid, and adenosine is administered to subjects including humans and animals such as livestock and pets.
- a hair growth method and a scalp condition ameliorating method are provided, comprising:
- the VEGF gene is expressed in dermal papilla cells and exhibits effects such as promotion of hair shaft growth, improvement in hair shaft elongation speed, improvement in maximum hair shaft length, and increase in hair shaft diameter in hair, hair, eyebrows and/or eyelashes. is said to contribute to Therefore, human dermal papilla cells were used to evaluate the enhancement of VEGF gene expression in each component.
- Human dermal papilla cells and medium Human dermal papilla cells (catalog number: CA60205a, Caucasian, 29-year-old male, Toyobo Co., Ltd. (Japan)) were purchased and prepared as described in the protocol. We maintained and cultured the cells and performed test evaluations.
- the FastGene RNA Basic Kit (catalog number: FG-80250, Nippon Genetics Co., Ltd. (Japan)) was used to collect total RNA from the cells.
- the FastGene RNA binding column was transferred to a new collection tube and set, 700 ⁇ L of washing buffer RW2 was added to the FastGene RNA binding column, and centrifuged at 10000 g for 1 minute at room temperature.
- the FastGene RNA binding column was transferred to a new collection tube, set, and centrifuged at 15000 rpm for 1 minute at room temperature.
- the FastGene RNA binding column was transferred to a new collection tube and set, 50 ⁇ L of elution buffer RE was added to the center of the FastGene RNA binding column membrane, and centrifuged at 10000 g for 1 minute at room temperature to collect the purified RNA.
- the concentration of the collected RNA was measured with NanoDrop Lite (catalog number: ND-LITE, Thermo Fisher Scientific Co., Ltd.) and stored at -80°C until the next cDNA conversion.
- FastGene scriptase II cDNA synthesis 5x Ready Mix (catalog number: NE-LS64, Nippon Genetics Co., Ltd. (Japan)) was used for cDNA synthesis.
- the total RNA produced in a new tube was diluted with RNase-Free Water so that the concentration was 20 ng/mL, and 4 ⁇ L of FastGene scriptase II cDNA synthesis 5 ⁇ Ready Mix was added to 16 ⁇ L of this sample solution and vortexed.
- a MiniAmp thermal cycler Thermo Fisher Scientific Co., Ltd.
- the cDNA synthesized by the above method was used for real-time PCR.
- Add each cDNA template dilution to a predetermined well of a 96-well plate, add THUNDERBIRD SYBR qPCR Mix (catalog number: QPS-201, Toyobo Co., Ltd. (Japan)) and primers, mix, and mix with QuantStudio 7 Flex Real - Gene expression was analyzed with Time PCR System (catalog number: 4485693, Thermo Fisher Scientific Co., Ltd.).
- As a PCR reaction 40 cycles of 95°C for 5 seconds, 60°C for 30 seconds, and 72°C for 30 seconds were performed.
- VEGF gene-specific primers used in the test and the GAPDH gene-specific primers used as internal standards are shown below.
- Primer for detecting VEGF gene expression Forward direction: atcttcaagccatcctgtgtgc (SEQ ID NO: 1) Reverse: caaggcccacagggattttc (SEQ ID NO: 2)
- Primer for detecting GAPDH gene expression Forward direction: catccctgcctctactggcgctgcc (SEQ ID NO: 3)
- the relative expression level of each gene was calculated as follows.
- the Ct value (PCR cycle number) was calculated from the intersection of the amplification curve of each gene and the threshold line.
- the value obtained by dividing the Ct value of the target gene by the Ct value of the internal standard GAPDH gene is the relative expression level.
- a mixture of palmitoyl dipeptide-5 diaminobutyroyl hydroxythreonine and palmitoyl dipeptide-5 diaminohydroxybutyric acid enhances the expression of VEGF gene in dermal papilla cells more than when adenosine acts, , Promotes hair shaft growth in eyebrows and/or eyelashes, improves hair shaft elongation speed, improves maximum hair shaft length, and increases hair shaft diameter.
- a mixture of palmitoyl dipeptide-5 diaminobutyroyl hydroxythreonine and palmitoyl dipeptide-5 diaminohydroxybutyrate combined with adenosine increased the expression of the VEGF gene in dermal papilla cells by palmitoyl dipeptide-5 diaminobutyroyl hydroxythreonine and Compared to a mixture of palmitoyl dipeptide-5 diaminohydroxybutyric acid or adenosine as an active ingredient, the expression of the VEGF gene in dermal papilla cells is significantly enhanced, and the hair, bristles, eyebrows and / or eyelashes It was confirmed that it is useful as an active ingredient of a hair restorer that exhibits the effects of promoting hair shaft growth, improving the rate of elongation of the hair shaft, improving the maximum length of the hair shaft, and further increasing the diameter of the hair shaft.
- palmitoyl dipeptide-5 diaminobutyroyl hydroxythreonine, palmitoyl dipeptide-5 diaminohydroxybutyric acid and adenosine are used as active ingredients of the hair restorer, so that hair, pubic hair, eyebrows and/or eyelashes are It is possible to provide a new hair restorer and a scalp care agent that exhibit the effect of promoting the growth of the hair shaft, the effect of improving the hair shaft elongation speed, the effect of improving the maximum length of the hair shaft, and the scalp care effect.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Birds (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
(1)ヒト毛乳頭細胞及び培地について
ヒト毛乳頭細胞(カタログ番号:CA60205a、白色人種、29歳男性由来、東洋紡株式会社(日本))を購入し、プロトコールに記載されるようにして細胞を維持・培養して試験評価を行った。
試験用薬剤として、以下の各濃度(終濃度)の薬剤溶液を調製し、使用した。
比較例1:アデノシン 100μM
比較例2:ミノキシジル 30μM
実施例1:パルミトイルジペプチド-5ジアミノブチロイルヒドロキシトレオニンおよびパルミトイルジペプチド-5ジアミノヒドロキシ酪酸の混合物 0.025%溶液
実施例2:パルミトイルジペプチド-5ジアミノブチロイルヒドロキシトレオニンおよびパルミトイルジペプチド-5ジアミノヒドロキシ酪酸の混合物 3%溶液
実施例3:パルミトイルジペプチド-5ジアミノブチロイルヒドロキシトレオニンおよびパルミトイルジペプチド-5ジアミノヒドロキシ酪酸の混合物 3%溶液、アデノシン 100μMの混合溶液
ヒト毛乳頭細胞を5×104個/ウェルとなるように、96ウェルプレートに播種した。CO2インキュベーター(5%CO2、37℃)内で、1日間培養後、各試験用薬剤を含む培地に置換した。その後、細胞プレートをCO2インキュベーターに戻し、さらに72時間培養した。培養後、各ウェルより、全RNAを抽出、回収して、それをcDNAに逆転写した。調製したcDNAを用いて、リアルタイムPCR法にてVEGF遺伝子の発現を測定した。内部標準としてGAPDH遺伝子を用い、陰性対照群との相対値としてVEGF遺伝子の発現量を算出した。
VEGF遺伝子発現検出用プライマー
順方向:atcttcaagccatcctgtgtgc(配列番号1)
逆方向:caaggcccacagggattttc(配列番号2)
GAPDH遺伝子発現検出用プライマー
順方向:catccctgcctctactggcgctgcc(配列番号3)
逆方向:ccaggatgcccttgagggggccctc(配列番号4)
各遺伝子の増幅曲線と閾値線との交点より、Ct値(PCRサイクル数)を算出した。目的遺伝子のCt値より内部標準GAPDH遺伝子のCt値で除した値が相対発現量となる。
ヒト毛乳頭細胞にパルミトイルジペプチド-5ジアミノブチロイルヒドロキシトレオニンおよびパルミトイルジペプチド-5ジアミノヒドロキシ酪酸の混合物を72時間作用させた後のVEGF遺伝子の発現量の変化を測定し、その結果を、図1に示した。
さらに、パルミトイルジペプチド-5ジアミノブチロイルヒドロキシトレオニンおよびパルミトイルジペプチド-5ジアミノヒドロキシ酪酸の混合物とアデノシンとを併用するものは、毛乳頭細胞におけるVEGF遺伝子の発現を、パルミトイルジペプチド-5ジアミノブチロイルヒドロキシトレオニンおよびパルミトイルジペプチド-5ジアミノヒドロキシ酪酸の混合物、もしくはアデノシンを有効成分とする場合に比して、毛乳頭細胞におけるVEGF遺伝子の発現をより有意に亢進し、頭髪、須毛、眉毛および/または睫毛毛における毛幹成長促進、毛幹伸長速度の向上、毛幹最大長の向上、毛幹径をより増大する効果を奏する育毛剤の有効成分として有用であることが確認された。
Claims (18)
- パルミトイルジペプチド-5ジアミノブチロイルヒドロキシスレオニンおよびパルミトイルジペプチド-5ジアミノヒドロキシ酪酸と、アデノシンとを有効成分として含有することを特徴とする育毛剤。
- パルミトイルジペプチド-5ジアミノブチロイルヒドロキシスレオニンおよびパルミトイルジペプチド-5ジアミノヒドロキシ酪酸を有効成分として含有することを特徴とする、アデノシンと併用するための育毛剤。
- アデノシンを有効成分として含有することを特徴とする、パルミトイルジペプチド-5ジアミノブチロイルヒドロキシスレオニンおよびパルミトイルジペプチド-5ジアミノヒドロキシ酪酸と併用するための育毛剤。
- 毛幹成長促進または発毛に用いるための、請求項1~請求項3のいずれか1項に記載の育毛剤。
- 毛幹伸長速度を向上させるために使用する、請求項1~請求項4のいずれか1項に記載の育毛剤。
- 毛幹最大長を向上させるために使用する、請求項1~請求項4のいずれか1項に記載の育毛剤。
- 毛幹径を増大させるために使用する、請求項1~請求項4のいずれか1項に記載の育毛剤。
- 毛数を増加させるために使用する、請求項1~請求項4のいずれか1項に記載の育毛剤。
- 溶液である、請求項1~請求項8のいずれか1項に記載の育毛剤。
- 頭髪、須毛、眉毛および/または睫毛用の、請求項1~請求項9のいずれか1項に記載の育毛剤。
- パルミトイルジペプチド-5ジアミノブチロイルヒドロキシスレオニンおよびパルミトイルジペプチド-5ジアミノヒドロキシ酪酸と、アデノシンとを、有効成分として製剤に含有させる工程を有することを特徴とする、育毛剤の製造方法。
- パルミトイルジペプチド-5ジアミノブチロイルヒドロキシスレオニンおよびパルミトイルジペプチド-5ジアミノヒドロキシ酪酸を有効成分として製剤に含有させる工程を有することを特徴とする、アデノシンと併用するための育毛剤の製造方法。
- アデノシンを有効成分として製剤に含有させる工程を有することを特徴とする、パルミトイルジペプチド-5ジアミノブチロイルヒドロキシスレオニンおよびパルミトイルジペプチド-5ジアミノヒドロキシ酪酸と併用するための育毛剤の製造方法。
- パルミトイルジペプチド-5ジアミノブチロイルヒドロキシスレオニンおよびパルミトイルジペプチド-5ジアミノヒドロキシ酪酸を含有する製剤と、アデノシンを含有する製剤とを含む、育毛剤のキット。
- パルミトイルジペプチド-5ジアミノブチロイルヒドロキシスレオニンおよびパルミトイルジペプチド-5ジアミノヒドロキシ酪酸を含有する製剤を含む、アデノシンと併用するための育毛剤のキット。
- アデノシンを含有する製剤を含む、パルミトイルジペプチド-5ジアミノブチロイルヒドロキシスレオニンおよびパルミトイルジペプチド-5ジアミノヒドロキシ酪酸と併用するための育毛剤のキット。
- パルミトイルジペプチド-5ジアミノブチロイルヒドロキシスレオニンおよびパルミトイルジペプチド-5ジアミノヒドロキシ酪酸と、アデノシンとを有効成分として投与することを特徴とする、育毛方法。
- 請求項1~請求項10のいずれか1項に記載の育毛剤を対象に投与することを含む育毛方法。
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/278,728 US20240139276A1 (en) | 2021-02-26 | 2022-02-25 | Hair growth agent |
JP2023502551A JPWO2022181786A1 (ja) | 2021-02-26 | 2022-02-25 | |
KR1020237032280A KR20230152072A (ko) | 2021-02-26 | 2022-02-25 | 육모제 |
CN202280008688.0A CN116916882A (zh) | 2021-02-26 | 2022-02-25 | 育毛剂 |
TW111107182A TW202302137A (zh) | 2021-02-26 | 2022-02-25 | 育毛劑 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021-031138 | 2021-02-26 | ||
JP2021031138 | 2021-02-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022181786A1 true WO2022181786A1 (ja) | 2022-09-01 |
Family
ID=83047567
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2022/008010 WO2022181786A1 (ja) | 2021-02-26 | 2022-02-25 | 育毛剤 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20240139276A1 (ja) |
JP (1) | JPWO2022181786A1 (ja) |
KR (1) | KR20230152072A (ja) |
CN (1) | CN116916882A (ja) |
TW (1) | TW202302137A (ja) |
WO (1) | WO2022181786A1 (ja) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012126671A (ja) * | 2010-12-15 | 2012-07-05 | Ltt Bio-Pharma Co Ltd | 育毛剤 |
JP2013151480A (ja) * | 2011-12-26 | 2013-08-08 | Rohto Pharmaceutical Co Ltd | 外用組成物の安定化方法 |
CN111329779A (zh) * | 2020-03-23 | 2020-06-26 | 烟台中科恩吉科创新产业园管理有限公司 | 一种促毛发增长的活性肽组合物及其应用 |
WO2021075219A1 (ja) * | 2019-10-18 | 2021-04-22 | 株式会社アジュバンコスメジャパン | 育毛剤 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1683509A4 (en) | 2003-11-11 | 2011-06-22 | Shiseido Co Ltd | METHOD AND COMPOSITION FOR THICKENING HAIR |
ES2358605T3 (es) | 2006-04-28 | 2011-05-12 | Dsm Ip Assets B.V. | Composición cosmética para estimular la síntesis de las proteínas de la membrana basal. |
-
2022
- 2022-02-25 TW TW111107182A patent/TW202302137A/zh unknown
- 2022-02-25 KR KR1020237032280A patent/KR20230152072A/ko unknown
- 2022-02-25 US US18/278,728 patent/US20240139276A1/en active Pending
- 2022-02-25 JP JP2023502551A patent/JPWO2022181786A1/ja active Pending
- 2022-02-25 WO PCT/JP2022/008010 patent/WO2022181786A1/ja active Application Filing
- 2022-02-25 CN CN202280008688.0A patent/CN116916882A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012126671A (ja) * | 2010-12-15 | 2012-07-05 | Ltt Bio-Pharma Co Ltd | 育毛剤 |
JP2013151480A (ja) * | 2011-12-26 | 2013-08-08 | Rohto Pharmaceutical Co Ltd | 外用組成物の安定化方法 |
WO2021075219A1 (ja) * | 2019-10-18 | 2021-04-22 | 株式会社アジュバンコスメジャパン | 育毛剤 |
CN111329779A (zh) * | 2020-03-23 | 2020-06-26 | 烟台中科恩吉科创新产业园管理有限公司 | 一种促毛发增长的活性肽组合物及其应用 |
Also Published As
Publication number | Publication date |
---|---|
US20240139276A1 (en) | 2024-05-02 |
JPWO2022181786A1 (ja) | 2022-09-01 |
TW202302137A (zh) | 2023-01-16 |
KR20230152072A (ko) | 2023-11-02 |
CN116916882A (zh) | 2023-10-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2636118B2 (ja) | 育毛剤 | |
JP2000226317A (ja) | 毛髪保護作用と毛髪減損の予防性並びにアンドロゲン性脱毛症の外因作用とその結果もたらされる毛髪減損の低下性において、改善された性質を有するヘアロ―ション | |
KR20060123256A (ko) | 모발의 태모화 방법 및 조성물 | |
WO2022181786A1 (ja) | 育毛剤 | |
WO2022265054A1 (ja) | 育毛剤 | |
WO2022265052A1 (ja) | 育毛剤 | |
WO2022265053A1 (ja) | 育毛剤 | |
EP2119431B1 (fr) | Composition contenant l'association de madécassoside et/ou de terminoloside et d'une arginine et/ou l'un de ses sels et/ou l'un de ses dérivés; utilisation de l'association pour induire et/ou stimuler la croissance de ces fibres kératiniques humaines et/ou freiner leur chute. | |
FR2984129A1 (fr) | Utilisation de la proteine mmp-12 dans la prevention et/ou le traitement des etats pelliculaires du cuir chevelu | |
WO2022181785A1 (ja) | 育毛剤 | |
JP7291333B2 (ja) | 育毛剤 | |
KR102035812B1 (ko) | 모발 성장 촉진제 | |
US9126056B2 (en) | Method of promoting hair growth | |
US10543227B2 (en) | Hair growth composition | |
WO2022124212A1 (ja) | 毛髪改善のための組成物 | |
JP2023025132A (ja) | スカルプケア剤 | |
JP2004331664A (ja) | ピリミジン−n−オキシド誘導体を含有する毛髪用組成物、ケラチン繊維の成長を刺激し及び/又は抜毛を減少させるためのその使用 | |
EP2465581B1 (en) | Non-therapeutic use of a composition for promoting hair growth | |
JP3624318B2 (ja) | 養毛剤 | |
AU2012100997A4 (en) | Hair regrowth and hair thickening formulation for mammalian hair | |
JP2001048756A (ja) | 養毛化粧料 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22759820 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2023502551 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280008688.0 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18278728 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 20237032280 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 22759820 Country of ref document: EP Kind code of ref document: A1 |